Arcturus Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Arcturus Therapeutics Holdings has been growing earnings at an average annual rate of 6.8%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 56.9% per year.
Key information
6.8%
Earnings growth rate
12.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 56.9% |
Return on equity | -27.8% |
Net Margin | -43.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat
May 11Revenue & Expenses Breakdown
How Arcturus Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 164 | -72 | 53 | 6 |
31 Mar 24 | 125 | -107 | 54 | 0 |
31 Dec 23 | 167 | -30 | 53 | 0 |
30 Sep 23 | 296 | 99 | 52 | 97 |
30 Jun 23 | 264 | 80 | 51 | 97 |
31 Mar 23 | 281 | 111 | 49 | 0 |
31 Dec 22 | 206 | 9 | 46 | 0 |
30 Sep 22 | 52 | -147 | 47 | 0 |
30 Jun 22 | 41 | -165 | 45 | 0 |
31 Mar 22 | 15 | -198 | 44 | 0 |
31 Dec 21 | 12 | -204 | 41 | 0 |
30 Sep 21 | 9 | -196 | 42 | 0 |
30 Jun 21 | 9 | -163 | 36 | 0 |
31 Mar 21 | 9 | -119 | 31 | 0 |
31 Dec 20 | 10 | -72 | 25 | 0 |
30 Sep 20 | 10 | -52 | 18 | 0 |
30 Jun 20 | 11 | -38 | 17 | 0 |
31 Mar 20 | 19 | -29 | 16 | 0 |
31 Dec 19 | 21 | -26 | 14 | 0 |
30 Sep 19 | 25 | -16 | 7 | 0 |
30 Jun 19 | 26 | -13 | 7 | 0 |
31 Mar 19 | 18 | -22 | 12 | 0 |
31 Dec 18 | 16 | -22 | 13 | 0 |
30 Sep 18 | 10 | -26 | 21 | 0 |
30 Jun 18 | 10 | -25 | 19 | 0 |
31 Mar 18 | 12 | -16 | 12 | 0 |
31 Dec 17 | 13 | -11 | 8 | 0 |
31 Dec 16 | 20 | -2 | 3 | 0 |
31 Dec 15 | 6 | -2 | 3 | 0 |
Quality Earnings: ARCT is currently unprofitable.
Growing Profit Margin: ARCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARCT is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare ARCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: ARCT has a negative Return on Equity (-27.83%), as it is currently unprofitable.